This study provides further insights into those preoperative parameters that predict side-specific risk of pathological stage in men undergoing radical prostatectomy (RP). The transrectal ultrasound-guided tissue biopsy cores obtained from the right and left sides of the prostate were collected in separate jars and examined independently according to the side of origin in 1250 men with clinically localized prostate cancer who underwent RP. The side-specific biopsy specimens were examined for Gleason score, number of positive cores, percentage of positive cores, percent tumor volume in the biopsy specimens and the presence of perineural invasion. All of the surgical specimens were processed and analyzed by pathologists at NYUMC using a standardized protocol. The surgical specimens were examined for side-specific extracapsular extension (ECE) and seminal vesicle invasion (SVI). Using a univariate analysis, age, serum prostate-specific antigen (PSA), prostate volume, clinical stage, Gleason score, number of positive biopsies, percent positive biopsy cores, percent volume of prostate cancer in cores and perineural invasion were all significant predictors of both ECE and SVI. A multivariate analysis was performed to determine the independent predictors of ECE and SVI. Serum PSA, biopsy Gleason score, percent volume of biopsy cores with cancer and perineural invasion were independent predictors of side-specific ECE. Age, serum PSA, Gleason score and prostate volume were independent predictors of side-specific SVI. Our study identified previously unrecognized independent predictors of side-specific ECE and SVI. Our study also provides evidence that the independent predictors of ECE and SVI are different.
Introduction
Partin et al. 1 reported that preoperative serum prostatespecific antigen (PSA) levels, biopsy Gleason score and clinical stage were independent predictors of pathological stage following radical prostatectomy (RP). On the basis of these observations, Partin tables were constructed to preoperatively ascertain the risk of extracapsular extension (ECE), seminal vesicle invasion (SVI) and pelvic lymph node invasion using categorical subgroups of PSA levels, Gleason score and clinical stage. These parameters were subsequently used by D'Amico et al. 2 to define three different risk groups for biochemical recurrence following RP. The Partin tables were recently updated to reflect a cohort of men diagnosed with prostate cancer in the PSA era. 3 The Partin tables, D'Amico risk groups and life expectancy tables (www.ssa.gov/OACT/stats/index.html) provide useful information for selecting appropriate candidates for RP. Instruments that combine clinical and pathological information provide more accurate predictive information regarding risk of disease progression following RP; 4 however, these instruments are not applicable for preoperative decision making.
The decision to preserve neurovascular bundles has definite implications regarding potency status following RP. [5] [6] [7] Although controversial, there is also some evidence that seminal vesicle preservation may also favorably impact potency. 8 The surgeon performing RP has to balance preservation of quality of life and achieving local disease control. It is unlikely that surgeons would preserve neurovascular bundles or seminal vesicles in cases where there exists a high probability of ECE or SVI, respectively.
Minimally invasive ablative therapies such as high intensity focused ultrasound 9, 10 and cryosurgery 11 do not typically target the seminal vesicles. Therefore, predicting SVI would be highly relevant for selecting candidates for these ablative therapies.
Taneja et al. 12 first reported on side-specific risk of ECE and SVI. In this study of 407 men undergoing RP, Gleason score and number of ipsilateral positive biopsy cores were significant predictors of side-specific risk of ECE.
This study of 1250 men with clinically localized prostate cancer undergoing RP provides further insight into preoperative parameters that predict side-specific risk of pathological findings.
Methods
Between October 2000 to June 2007, 1412 men underwent open radical retropubic prostatectomy by a single surgeon using a previously described technique. 13 All of the men signed informed consent providing permission to prospectively collect baseline, surgical, pathological and outcomes information. In 1250 of these cases, the tissue biopsy cores from the right and left sides of the prostate were collected in separate jars and examined according to the side of origin. All of the biopsy specimens were re-read by pathologists at NYU Medical Center before RP. The side-specific biopsy specimens were examined for Gleason score, number of positive cores, percentage of positive cores, percent tumor volume in the biopsy specimens and the presence of perineural invasion. All of the surgical specimens were processed and analyzed by pathologists at NYUMC using a standardized protocol.
14 ECE and SVI were reported independently for the right and left sides of the prostate.
The overwhelming majority of the transrectal ultrasound-guided prostate biopsies were not performed at NYU Medical Center, and therefore the information regarding prostate volume was not uniformly available. Therefore, prostate volumes were calculated directly from the measurements of the prostate surgical specimen using the formula (length) Â (width) Â (height) Â 0.52.
Statistical analysis
The mean, median and range of all relevant preoperative variables were calculated for all 1250 patients. Categorical variables were initially assessed using a univariate w 2 analysis to ascertain their value for significantly predicting the presence of ECE and SVI. Multivariate logistic regression models were then used to analyze whether these preoperative variables were also independent significant predictors of the presence of ECE and SVI. The significant value was set at Po0.05. All analyses were performed using SPSS for Windows, version 11.0 (SPSS Inc, Chicago, IL).
Results
The characteristics of the study population are summarized in Table 1 .
The preoperative parameters predicting ECE and SVI are summarized in Table 2 . Using a univariate analysis, age, serum PSA, prostate volume, clinical stage, Gleason score, number of positive biopsies, percent positive biopsy cores, percent volume of prostate cancer in cores and perineural invasion were all significant predictors of both ECE and SVI.
A multivariate analysis was performed to determine the independent predictors of ECE and SVI (Table 3) . Serum PSA, biopsy Gleason score, percent volume of biopsy cores with cancer and perineural invasion were independent predictors of side-specific ECE. Prostate volume approached statistical significance as an independent predictor of side-specific ECE. Age, serum PSA, Gleason score and prostate volume were independent predictors of side-specific SVI.
Discussion
The goal of RP for the treatment of localized prostate cancer is to cure the disease while restoring quality of life. Nerve sparing [5] [6] [7] and possibly seminal vesicle sparing 8 techniques increase the likelihood of preserving erectile function. It is conceivable that in higher risk cases of clinically localized prostate cancer, preserving these structures may compromise local disease control. One of the primary objectives of predicting pathological stage is to guide the surgeon regarding the potential consequences of preserving the neurovascular bundles or seminal vesicles. Every surgeon will have different thresholds for preserving these structures based upon baseline potency status, priorities of the surgical candidate and the perceived risk of compromising local disease control. Ideally, the surgeon needs to know the side-specific risk of ECE and SVI, as decisions to preserve the two neurovascular bundles and seminal vesicles should be made independently. Side-specific factors associated with ECE and SVI A Sankin et al Cryosurgery 11 and high intensity focused ultrasound 9,10 are ablative approaches for treating prostate cancer that spares the seminal vesicles. Therefore, knowing the risks of SVI is important for the proper selection of candidates for these therapies. There is increasing interest in using these focal ablative therapies to completely eradicate the prostate cancer while preserving the neurovascular bundles 15 and increasing potency rates. Knowing the side-specific risk of ECE is essential for proper selection of candidates for these ablative therapies.
Between October 2000 to June 2007, 1412 men underwent RP by a single surgeon at NYU medical center. Almost all of these cases were biopsied in the community.
Of these 1412 cases, 1250 (89%) had their biopsy specimens collected and analyzed independently according to the side of origin. Therefore, the standard of urological practice in the community is to separately collect biopsy specimens according to the side of origin. Thus, ascertaining side-specific risk of ECE and SVI is applicable in almost all cases and requires no additional cost.
Our univariate analysis showed that age, preoperative PSA levels and prostate volume predicted both the risk of ECE and SVI. Side-specific clinical stage, biopsy Gleason score, number of positive tissue cores, percent positive tissue cores, percent tumor volume and perineural invasion were predictive variables for the sidespecific risk of both ECE and SVI. In a multivariate analysis, serum PSA, side-specific biopsy Gleason score, percentage of tumor volume in surgical specimen and perineural invasion were independent predictors of ECE. Age, serum PSA, prostate volume and side-specific Gleason score were independent predictors of sidespecific SVI.
Perineural invasion in the biopsy has been previously observed to be a predictor of ECE. 16, 17 To our knowledge, perineural invasion has not been previously investigated as an independent predictor of side-specific risk of ECE or SVI. In our study, perineural invasion was an independent risk factor for ECE and not SVI. The observed increased side-specific risk of ECE in cases with perineural invasion may be explained by the tumors ability to gain access to the extracapsular space by infiltrating and following the course of the prostatic nerves, which emanates from the neurovascular bundle. 18 The neurovascular bundle is in close proximity to the prostatic capsule and not the seminal vesicle.
Freedland et al. 18 has observed that smaller prostates have a greater risk of both ECE and SVI. Our univariate analysis confirmed earlier reports that prostate volume Side-specific factors associated with ECE and SVI A Sankin et al was inversely associated with both ECE and SVI. Eightyfive percent of men in our study cohort were clinical T1c, indicating that PSA elevation drives the detection of cancer in the majority of our surgical candidates. The PSA elevation in smaller glands is more likely due to cancer and not BPH. Therefore, smaller glands are more likely to have a relatively greater volume of cancer than larger glands at similar PSA levels. In addition, a cancer of equal volume is more likely to encroach upon the seminal vesicle and prostatic capsule in smaller glands, as it has a shorter distance to traverse to invade these structures. The Partin tables are widely used for preoperatively assessing risk of specimen ECE or SVI. Partin et al.
1 did not include biopsy tumor volume, perineural invasion, prostate volume or age in their original tables predicting ECE and SVI. All these parameters in this study were independent predictors of side-specific ECE or SVI. The justification for not including biopsy prostate tumor volume in the Partin tables was that biopsy tumor volume in the Hopkins series was not an independent predictor of pathological stage. 19 Tumor volume in the biopsy may have been an independent predictor of pathological stage if the tumor volume was analyzed according to the side of origin. Our study provides compelling evidence that several additional factors beyond Gleason score, clinical stage and serum PSA should be added to models for predicting ECE or SVI. One disadvantage of expressing risk of ECE and SVI in table form is that it is cumbersome to include more than three independent variables.
Nomograms represent a more useful instrument than tables for predicting outcomes involving multiple independent factors. Ohori, et al. 20 developed a nomogram that predicted side-specific risk of ECE using baseline clinical and biopsy information. The nomogram included serum PSA, side-specific clinical stage, Gleason score, percent positive tissue cores and percent cancer in tissue cores. All of these factors were found to be independent predictors of risk of ECE. Perineural invasion and prostate volume were not examined as risk factors for ECE in this model.
Our univariate analysis shows that the same variables predict risk of side-specific ECE and SVI. However, the independent predictors of side-specific ECE and SVI are different. Therefore, different nomograms need to be developed for predicting side-specific risks of ECE and SVI.
Conclusion
The goals of RP and ablative therapies are to cure the disease while maintaining quality of life. Preserving the neurovascular bundles and possibly the seminal vesicles increases the likelihood of preserving erectile function. The decision to preserve neurovascular bundle and seminal vesicle at the time of RP or ablative therapies should be guided by the side-specific risk of ECE and SVI. Our study shows the feasibility of assessing sidespecific risk of ECE and SVI. This study is the largest series examining the side-specific risk of ECE and SVI. We identified previously unrecognized variables that are independent predictors of both ECE and SVI. Our study provides compelling evidence that the independent predictors of ECE and SVI are different. Surgeons performing nerve sparing RP or focal ablative therapies must recognize the factors predicting side-specific risk of ECE and SVI, so that they can properly select candidates for interventions designed to preserve neurovascular bundles or seminal vesicles.
